专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06902743B1 Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix 失效
标题翻译：用生物可降解生物相容的聚合物基质包裹的生物活性物质的治疗和预防感染
公开(公告)号：US06902743B1
公开(公告)日：2005-06-07
申请号：US09055505
申请日：1998-04-06
申请人： Jean A. Setterstrom , Thomas R. Tice , Elliot Jacob , Robert H. Reid , John van Hamont , Edgar C. Boedecker , Ramassubbu Jeyanthi , Phil Friden , F. Donald Roberts , Charles E. McQueen , Apurba Bhattacharjee , Alan Cross , Jerald Sadoff , Wendell Zollinger
发明人： Jean A. Setterstrom , Thomas R. Tice , Elliot Jacob , Robert H. Reid , John van Hamont , Edgar C. Boedecker , Ramassubbu Jeyanthi , Phil Friden , F. Donald Roberts , Charles E. McQueen , Apurba Bhattacharjee , Alan Cross , Jerald Sadoff , Wendell Zollinger
IPC分类号： A61K9/16 , A61K9/50 , A61K38/17 , A61K9/14 , A61K39/40 , A61K9/48 , A61K9/26
CPC分类号： A61K9/5026 , A61K9/1611 , A61K9/1617 , A61K9/1641 , A61K9/1647 , A61K38/1709 , Y02A50/414 , Y02A50/423 , Y02A50/478 , Y02A50/48 , Y02A50/491
摘要： Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer having a molar composition of lactide/glycolide from 90/10 to 40/60, which may contain a pharmaceutically-acceptable adjuvant, as a blend of uncapped free carboxyl end group and end-capped forms ranging to ratios from 100/0 to 1/99.
摘要翻译：新型无爆发，持续释放的生物相容性和可生物降解的微胶囊，可以编程为在水性生理环境中从1-100天的可变持续时间释放其活性核心。该微胶囊包含多肽或其它生物活性剂的核心，其包封在聚（丙交酯/乙交酯）共聚物基质中，其具有90/10至40/60的丙交酯/乙交酯的摩尔组成，其可含有药学上可接受的佐剂，作为未加帽的游离羧基端基和封端形式的混合物，其比例为100/0至1/99。

2. 发明授权

US06844010B1 Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix 失效
标题翻译：用生物可降解生物相容的聚合物基质包封的生物活性物质进行治疗和预防感染
公开(公告)号：US06844010B1
公开(公告)日：2005-01-18
申请号：US09618577
申请日：2000-07-18
申请人： Jean A. Setterstrom , John E. Van Hamont , Robert H. Reid , Elliot Jacob , Ramasubbu Jeyanthi , Edgar C. Boedeker , Charles E. McQueen , Daniel L. Jarboe , Frederick Cassels , William Brown , Curt Thies , Thomas R. Tice , F. Donald Roberts , Phil Friden
发明人： Jean A. Setterstrom , John E. Van Hamont , Robert H. Reid , Elliot Jacob , Ramasubbu Jeyanthi , Edgar C. Boedeker , Charles E. McQueen , Daniel L. Jarboe , Frederick Cassels , William Brown , Curt Thies , Thomas R. Tice , F. Donald Roberts , Phil Friden
IPC分类号： A61K9/16 , A61K9/50 , A61K9/52 , A61K38/17 , A61K38/19 , A61K39/00 , A61K39/02 , A61K39/108 , A61K39/29 , F23G5/50 , G05B23/02
CPC分类号： A61K39/292 , A61K9/1611 , A61K9/1617 , A61K9/1635 , A61K9/1641 , A61K9/1647 , A61K9/5026 , A61K9/5031 , A61K38/09 , A61K38/1729 , A61K39/00 , A61K39/0258 , A61K39/12 , A61K45/06 , A61K2039/545 , A61K2039/55505 , A61K2039/55555 , C12N2730/10134 , Y02A50/464 , Y02A50/474 , Y02A50/48 , Y02A50/487 , Y02A50/489 , Y02A50/491 , A61K2300/00
摘要： Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group, and end-capped forms ranging in ratios from 100/0 to 1/99.
摘要翻译：新型无爆发，持续释放的生物相容性和可生物降解的微胶囊，可以编程为在水性生理环境中从1-100天的可变持续时间释放其活性核心。微胶囊由多肽或其他生物活性剂的核心组成，其包封在聚（丙交酯/乙交酯）共聚物的基质中，其可以含有药学上可接受的佐剂，作为被覆盖的游离羧基端基和封端的共轭物形式范围从100/0至1/99。

3. 发明授权

US06309669B1 Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix 失效
标题翻译：用生物可降解生物相容的聚合物基质包封的生物活性物质进行治疗和预防感染
公开(公告)号：US06309669B1
公开(公告)日：2001-10-30
申请号：US08789734
申请日：1997-01-27
申请人： Jean A. Setterstrom , John E. Van Hamont , Robert H. Reid , Elliot Jacob , Ramasubbu Jeyanthi , Edgar C. Boedeker , Charles E. McQueen , Daniel L. Jarboe , Frederick Cassels , William Brown , Curt Thies , Thomas R. Tice , F. Donald Roberts , Phil Friden
发明人： Jean A. Setterstrom , John E. Van Hamont , Robert H. Reid , Elliot Jacob , Ramasubbu Jeyanthi , Edgar C. Boedeker , Charles E. McQueen , Daniel L. Jarboe , Frederick Cassels , William Brown , Curt Thies , Thomas R. Tice , F. Donald Roberts , Phil Friden
IPC分类号： A61K952
CPC分类号： A61K39/292 , A61K9/1611 , A61K9/1617 , A61K9/1635 , A61K9/1641 , A61K9/1647 , A61K9/5026 , A61K9/5031 , A61K38/09 , A61K38/1729 , A61K39/00 , A61K39/0258 , A61K39/12 , A61K45/06 , A61K2039/545 , A61K2039/55505 , A61K2039/55555 , C12N2730/10134 , Y02A50/464 , Y02A50/474 , Y02A50/48 , Y02A50/487 , Y02A50/489 , Y02A50/491 , A61K2300/00
摘要： Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.
摘要翻译：新型无爆发，持续释放的生物相容性和可生物降解的微胶囊，可以编程为在水性生理环境中从1-100天的可变持续时间释放其活性核心。微胶囊包含多肽或其他生物活性剂的核心，其包封在聚（丙交酯/乙交酯）共聚物基质中，其可以含有药学上可接受的佐剂，作为上覆游离羧基端基和封端形式的共混物范围从100/0至1/99。

4. 发明授权

US06410056B1 Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix 失效
标题翻译：用包封在可生物降解的聚合物基质内的抗生素进行细菌感染的化学治疗
公开(公告)号：US06410056B1
公开(公告)日：2002-06-25
申请号：US08446148
申请日：1995-05-22
申请人： Jean A. Setterstrom , Elliot Jacob , Thomas R. Tice
发明人： Jean A. Setterstrom , Elliot Jacob , Thomas R. Tice
IPC分类号： A61K950
CPC分类号： A61K9/1647 , Y02A50/478 , Y10T428/2989
摘要： Biodegradable pharmaceutical compositions and method for treating bacterial infections therein.
摘要翻译：可生物降解的药物组合物及其中治疗细菌感染的方法

5. 发明授权

US08858974B2 Device and methods for treating paranasal sinus conditions 有权
标题翻译：用于治疗鼻旁窦病症的装置和方法
公开(公告)号：US08858974B2
公开(公告)日：2014-10-14
申请号：US12270695
申请日：2008-11-13
申请人： Donald J. Eaton , Thomas R. Tice , David B. Downie , Patrick A. Arensdorf , Rodney Brenneman , Danielle L. Biggs
发明人： Donald J. Eaton , Thomas R. Tice , David B. Downie , Patrick A. Arensdorf , Rodney Brenneman , Danielle L. Biggs
IPC分类号： A61F13/00 , A61N1/30 , A61B17/08 , A61K31/573 , A61K31/58 , A61B17/24 , A61K9/70 , A61K9/00 , A61F2/18 , A61K9/16
CPC分类号： A61B17/24 , A61F2/186 , A61K9/0043 , A61K9/1647 , A61K9/70 , A61K31/573 , A61K31/58 , A61K47/14 , A61K47/34 , A61M29/00
摘要： Described here are paranasal sinus devices for treating paranasal sinus conditions. The devices include a cavity member, ostial member, and nasal portion. One or more of the cavity member, ostial member, and nasal portion may deliver an active agent for sustained release to treat the paranasal sinus condition. Exemplary paranasal sinus conditions are sinus inflammation due to functional endoscopic sinus surgery (FESS) and rhinosinusitis.
摘要翻译：这里描述了用于治疗鼻旁窦状况的鼻旁窦装置。这些装置包括空腔构件，口部构件和鼻部。空腔构件，口腔构件和鼻部分中的一个或多个可以递送用于持续释放的活性剂以治疗鼻旁窦状况。由于功能性内镜鼻窦手术（FESS）和鼻鼻窦炎，示例性的鼻旁窦状况是鼻窦炎症。

6. 发明申请

US20110236497A1 Compositions and Methods for Improved Retention of a Pharmaceutical Composition at a Local Administration Site 有权
标题翻译：用于在本地管理场所改进药物组合物保留的组合物和方法
公开(公告)号：US20110236497A1
公开(公告)日：2011-09-29
申请号：US13074542
申请日：2011-03-29
申请人： Thomas R. Tice , Kevin W. Burton
发明人： Thomas R. Tice , Kevin W. Burton
IPC分类号： A61K9/50 , A61K47/42 , A61K47/36 , A61K47/04 , A61K47/02 , C08G63/91
CPC分类号： A61K9/0024 , A61K9/0085 , A61K9/1647 , A61K9/1652 , A61K47/36 , Y10S260/31
摘要： Disclosed herein are compositions comprising cross-linkers for cross-linking a retention vehicle polymer. The compositions are particularly useful for local administration of a bioactive agent, wherein prolonged or extended availability of the bioactive agent at the site of administration is desired. Also disclosed are methods of delivering the compositions to a subject.
摘要翻译：本文公开了包含用于交联保留载体聚合物的交联剂的组合物。组合物特别可用于局部施用生物活性剂，其中需要在给药部位延长或延长生物活性剂的可用性。还公开了将组合物递送到受试者的方法。

7. 发明申请

US20080305115A1 Reduced-mass, long-acting dosage forms 审中-公开
标题翻译：减质量，长效剂型
公开(公告)号：US20080305115A1
公开(公告)日：2008-12-11
申请号：US12157368
申请日：2008-06-09
申请人： Thomas R. Tice , Peter Markland , Jay K. Staas
发明人： Thomas R. Tice , Peter Markland , Jay K. Staas
IPC分类号： A61K39/395 , A61K31/7088
CPC分类号： C07K16/00 , A61K9/0048 , A61K9/0051 , A61K9/1647 , A61K31/7088 , A61K2039/505
摘要： Methods and compositions are disclosed whereby free antibody or nucleic acid co-administered with a long-acting formulation, such as a microparticle or implant, containing the antibody or nucleic acid to achieve a long duration of antibody or nucleic acid release. One result is that less of the long-acting formulation excipient or polymer is needed allowing for small-volume administrations as required, for example, for ocular, intra-dermal, orthopedic, brain and spinal delivery. In one aspect, the free antibody or nucleic acid alone has efficacy for an extended period, during which time, very little or no long-acting formulation antibody or nucleic acid is released. In one aspect, after the free antibody or nucleic acid has diminished activity, is gone, or no longer has activity, the long-acting formulation antibody or nucleic acid begins to release for a desired preprogrammed duration to provide long-acting durations. Less formulation mass is needed because the entire antibody or nucleic acid is not encapsulated or implanted with encapsulation or implant excipient or polymer. In addition, more antibody or nucleic acid can be administered to afford longer-acting formulations.
摘要翻译：公开了方法和组合物，其中游离抗体或核酸与包含抗体或核酸的长效制剂如微粒或植入物共同施用以实现长时间的抗体或核酸释放。一个结果是需要较少的长效制剂赋形剂或聚合物，允许根据需要进行小批量给药，例如用于眼部，皮内，矫形，脑和脊柱递送。在一个方面，单独的游离抗体或核酸具有长时间的功效，在此期间很少或没有长效的制剂抗体或核酸被释放。一方面，在游离抗体或核酸活性降低，消失或不再具有活性之后，长效制剂抗体或核酸开始释放所需的预编程持续时间以提供长效持续时间。需要较少的制剂质量，因为整个抗体或核酸不被包封或植入赋形剂或聚合物包封或植入。此外，可以施用更多的抗体或核酸以提供长效制剂。

8. 发明授权

US06517859B1 Microcapsules for administration of neuroactive agents 失效
公开(公告)号：US06517859B1
公开(公告)日：2003-02-11
申请号：US08268177
申请日：1994-06-29
申请人： Thomas R. Tice , Deborah L. Dillon , David W. Mason , Amanda McRae-McFarlane , Annica B. Dahlstrom
发明人： Thomas R. Tice , Deborah L. Dillon , David W. Mason , Amanda McRae-McFarlane , Annica B. Dahlstrom
IPC分类号： A61F200
CPC分类号： A61K31/135 , A61K9/0085 , A61K9/1647 , A61K9/5068 , Y10S514/963 , Y10S977/907
摘要： The present invention relates to polymeric microspheres as injectable, drug-delivery vehicles for use to deliver bioactive agents to sites within the central nervous system, and for the stimulation of nerve fiber growth by implanting such microspheres within the central nervous system of a patient. Microspheres of less than 45 &mgr;m, preferably less than about 20 &mgr;m, and preferably about 0.1 &mgr;m to about 10 &mgr;m in mean diameter according to the present invention are also selectively taken-up and into astrocytes when delivered directly into the nervous tissues.

9. 发明授权

US06312731B1 Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof 有权
标题翻译：用于诱导或增强免疫应答的快速释放包封的生物活性剂及其使用方法
公开(公告)号：US06312731B1
公开(公告)日：2001-11-06
申请号：US09143162
申请日：1998-08-28
申请人： Jay K. Staas , Thomas R. Tice , Syamal Raychaudhuri , Paul R. Sleath
发明人： Jay K. Staas , Thomas R. Tice , Syamal Raychaudhuri , Paul R. Sleath
IPC分类号： A61F202
CPC分类号： A61K39/39 , A61K9/1617 , A61K9/1635 , A61K9/1647 , A61K9/1652 , A61K2039/55555 , A61K2039/57 , Y02A50/412 , Y10T428/2985
摘要： A composition for inducing or potentiating an immune response, preferably a CTL, T helper cell, or neutralizing antibody response in a subject, comprising an antigen and/or a non-antigen bioactive agent capable of inducing or potentiating such an immune response encapsulated in a polymeric composition, wherein the polymeric composition comprises a blend of (a) a polymer present in an amount sufficient to provide structural integrity to the polymeric composition, and (b) a rapidly biodegradable component, a rapidly dissolving component, a rapidly swelling component, or a component that causes osmotic rupture of the encapsulated polymeric composition is disclosed. Single polymer compositions for achieving such an immune response are also disclosed. Methods for inducing or potentiating a CTL, T helper cell or neutralizing antibody response using the above-identified compositions are disclosed.
摘要翻译：用于诱导或增强受试者中的免疫应答，优选CTL，T辅助细胞或中和抗体应答的组合物，其包含抗原和/或非抗原生物活性剂，其能够诱导或增强包封在聚合物组合物，其中所述聚合物组合物包含（a）以足以提供与所述聚合物组合物的结构完整性的量存在的聚合物的共混物，和（b）快速可生物降解的组分，快速溶解组分，快速溶胀组分或公开了引起包封的聚合物组合物渗透破裂的组分。也公开了用于实现这种免疫应答的单一聚合物组合物。公开了使用上述组合物诱导或增强CTL，T辅助细胞或中和抗体应答的方法。

10. 发明授权

US6024983A Composition for delivering bioactive agents for immune response and its preparation 失效
标题翻译：用于递送免疫应答生物活性剂及其制备的组合物
公开(公告)号：US6024983A
公开(公告)日：2000-02-15
申请号：US116802
申请日：1993-09-07
申请人： Thomas R. Tice , Richard M. Gilley , John H. Eldridge , Jay K. Staas
发明人： Thomas R. Tice , Richard M. Gilley , John H. Eldridge , Jay K. Staas
IPC分类号： A61K9/00 , A61K9/16 , A61K9/50 , A61K9/52 , A61K31/216 , A61K38/00 , A61K39/085 , A61K39/12 , A61K39/39
CPC分类号： A61K31/216 , A61K9/1635 , A61K9/1647 , A61K9/5084 , A61K2039/541 , A61K2039/55555 , A61K38/00 , Y10S424/81 , Y10S514/885 , Y10S514/888 , Y10S514/889 , Y10S514/958 , Y10S514/963 , Y10T428/2985 , Y10T428/2989
摘要： A method, and compositions for use therein capable, of delivering a bioactive agent to an animal entailing the steps of encapsulating effective amounts of the agent in a biocompatible excipient to form microcapsules having a size less than approximately ten micrometers and administering effective amounts of the microcapsules to the animal. A pulsatile response is obtained, as well as mucosal and systemic immunity.
摘要翻译：一种用于其中的方法和组合物，其能够将生物活性剂递送到动物，其包括将有效量的试剂包封在生物相容性赋形剂中以形成尺寸小于约十微米的微胶囊并施用有效量的微胶囊给动物获得脉动响应，以及粘膜和全身免疫。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式